{
    "doi": "https://doi.org/10.1182/blood.V112.11.346.346",
    "start_url": "https://ashpublications.org/blood/search-results?sort=Date+-+Oldest+First&f_ArticleTypeDisplayName=Meeting+Report&fl_SiteID=1000001&page=1182",
    "start_url_page_num": 1182,
    "is_scraped": "1",
    "article_title": "Non-Myeloablative Hematopoietic Stem Cell Transplantation in Older Patients with AML and MDS: Results from the Center for International Blood and Marrow Transplant Research (CIBMTR) ",
    "article_date": "November 16, 2008",
    "session_type": "Clinical Results - Allogeneic Matched Related Donor Transplantation",
    "topics": [
        "hematopoietic stem cell transplantation",
        "older adult",
        "transplantation",
        "allogeneic hematopoietic stem cell transplant",
        "allografting",
        "complete remission",
        "follow-up",
        "graft-versus-host disease",
        "graft-versus-host disease, chronic",
        "cyclosporine"
    ],
    "author_names": [
        "Brian McClune, DO",
        "Daniel J. Weisdorf, MD",
        "John F. DiPersio, MD, PhD",
        "Armand Keating, MD",
        "Tanya L. Pedersen",
        "Gisela Tunes da Silva, PhD.",
        "J. Sierra, MD",
        "Martin S. Tallman, MD",
        "Sergio A. Giralt"
    ],
    "author_affiliations": [
        [
            "University of Minnesota, Minneapolis, MN, USA"
        ],
        [
            "University of Minnesota, Minneapolis, MN"
        ],
        [
            "School of Medicine, Washington University, Saint Louis, MO, USA"
        ],
        [
            "Princess Margaret Hospital, Toronto, ON, Canada"
        ],
        [
            "CIBMTR, Milwaukee, WI"
        ],
        [
            "Medical College of Wisconsin, Milwaukee, WI"
        ],
        [
            "Clinical Hematology, Hospital De Sant Pau, Barcelona, Spain"
        ],
        [
            "Northwestern University Feinberg School of Medicine, Chicago, IL, USA"
        ],
        [
            "Stem Cell Transplantation and Cellular Therapy, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA"
        ]
    ],
    "first_author_latitude": "44.97399",
    "first_author_longitude": "-93.2277285",
    "abstract_text": "Background: AML and MDS disproportionately affect older-aged individuals. Hematopoietic cell transplantation (HCT) is the best established curative therapy but is generally not offered due to concerns about toxicity and poor outcome. Reduced-intensity conditioning (RIC) regimens have been developed to allow allografting in older patients; however, there is a paucity of data to support transplantation in patients over 65 years of age. Purpose: To better study age as a predictor of outcome, we retrospectively analyzed data reported to the CIBMTR from 1995\u20132005 among patients receiving RIC HCT for MDS (551 patients) and AML (565 patients) in first complete remission (CR). Patient and Methods: Outcomes analyzed for both disease groups included transplant-related mortality (TRM), engraftment, incidence of acute and chronic graft-versus-host disease (GVHD), leukemia-free (LFS) and overall survival (OS). Patients were stratified according to age cohorts for comparison: 40\u201354, 54\u201359, 60\u201364 and \u226565 years. Results: Clinical characteristics were well matched across age cohorts but notably, most AML patients presented with de novo disease (P=0.001) and received their allograft from a matched related donor (MRD) (P=0.001) with 51% of patients \u226565 years having a MRD. MDS patients more often had unrelated donors (URD), especially in the older cohorts (73% for \u2265 65 years); but donor type was not significantly different between groups. Most patients received peripheral blood (PB) allografts (76\u201397%), fludarabine-containing regimens for conditioning and cyclosporine-containing regimens for GVHD prophylaxis. Univariate analysis demonstrated no statistically significant differences in TRM across age cohorts and no overall difference in occurrence of acute (31\u201335% at 100 days) or chronic GVHD (36\u201353% at 2 years). Relapse rates were similar across all age groups (29\u201339% at 3 years) (Table). Multivariate analysis revealed no statistically significant impact of age on TRM, relapse, LFS, or OS (all p > 0.4). Disease and status at transplant were significant risk factors for OS/LFS at 1 year while affecting TRM/relapse at 2 years. Performance status and HLA disparity were also significant at 2 years for nearly all outcomes. Conclusion: 1. The outcomes for older adults undergoing allogeneic HCT are not significantly different than for younger adults, even after adjusting for multiple risk factors; 2. Age by itself should not be the limiting factor for proceeding to allogeneic HCT in older patients with AML or MDS; 3. Continued participation in clinical trials should be encouraged to explore strategies that could improve treatment outcome. Univariate probabilities of patients age \u226540 years receiving allogeneic HCT for AML/MDS in first complete remission reported to the CIBMTR, 1995\u20132005.  . . N . 40\u201354 . N . 55\u201360 . N . 60\u201364 . N . >65 . AML            TRM  220  150  132  63   100 days  11 (7\u201316)%  6 (3\u201310)%  13 (8\u201320)%  10 (4\u201318)%  1 year  20 (15\u201326)%  18 (12\u201324)%  24 (17\u201333)%  30 (19\u201342)%  Relapse           1 year  27 (21\u201333)%  34 (26\u201342)%  31 (23\u201340)%  22 (12\u201333)%  3 years  32 (26\u201339)%  35 (27\u201343)%  39 (30\u201349)%  33 (21\u201346)%  LFS           1 year  53 (46\u201360)%  49 (41\u201358)%  44 (35\u201353)%  48 (36\u201361)%  3 years  43 (36\u201351)%  41 (32\u201350)%  27 (19\u201337)%  34 (22\u201347)%  OS           100 days  84 (78\u201388)%  92 (87\u201396)%  83 (76\u201389)%  89 (80\u201395)%  1 year  59 (52\u201365)%  60 (52\u201368)%  51 (42\u201360)%  51 (39\u201364)%  3 years  45 (40\u201354)%  47 (42\u201359)%  30 (25\u201343)%  36(24\u201349)% Follow-up (months)   37 (2\u2013110)  25 (1\u201387)  36 (3\u201396)  29 (3\u201359) MDS  TRM  219  150  127  55   100 days  17 (13\u201323)%  17 (11\u201323)%  14 (9\u201321)%  19 (9\u201330)%  1 year  31 (24\u201337)%  33 (25\u201341)%  32 (24\u201341)%  34 (22\u201347)%  Relapse          1 year  26 (20\u201332)%  27 (20\u201335)%  26 (18\u201334)%  25 (14\u201337)%  3 years  29 (23\u201335)%  29 (22\u201337)%  31 (23\u201340)% higher  33 (20\u201347)%  LFS           1 year  43 (36\u201350)%  40 (32\u201349)%  43 (34\u201351)%  42 (29\u201356)%  3 years  36 (29\u201343)%  27 (\u20132035)%  29 (21\u201339)%  23 (12\u201338)%  OS           100 days  77 (71\u201382)%  77 (70\u201383)%  81 (74\u201387)%  76 (64\u201387)%  1 year  50 (43\u201356)%  46 (38\u201354)%  53 (44\u201362)%  48 (35\u201361)%  3 years  39 (32\u201346)%  29 (22\u201337)%  30 (21\u201340)%  29 (17\u201343)% Follow-up (months)   36 (2\u201386)  40 (3\u201386)  35 (3\u201368)  36 (3\u201385) . . N . 40\u201354 . N . 55\u201360 . N . 60\u201364 . N . >65 . AML            TRM  220  150  132  63   100 days  11 (7\u201316)%  6 (3\u201310)%  13 (8\u201320)%  10 (4\u201318)%  1 year  20 (15\u201326)%  18 (12\u201324)%  24 (17\u201333)%  30 (19\u201342)%  Relapse           1 year  27 (21\u201333)%  34 (26\u201342)%  31 (23\u201340)%  22 (12\u201333)%  3 years  32 (26\u201339)%  35 (27\u201343)%  39 (30\u201349)%  33 (21\u201346)%  LFS           1 year  53 (46\u201360)%  49 (41\u201358)%  44 (35\u201353)%  48 (36\u201361)%  3 years  43 (36\u201351)%  41 (32\u201350)%  27 (19\u201337)%  34 (22\u201347)%  OS           100 days  84 (78\u201388)%  92 (87\u201396)%  83 (76\u201389)%  89 (80\u201395)%  1 year  59 (52\u201365)%  60 (52\u201368)%  51 (42\u201360)%  51 (39\u201364)%  3 years  45 (40\u201354)%  47 (42\u201359)%  30 (25\u201343)%  36(24\u201349)% Follow-up (months)   37 (2\u2013110)  25 (1\u201387)  36 (3\u201396)  29 (3\u201359) MDS  TRM  219  150  127  55   100 days  17 (13\u201323)%  17 (11\u201323)%  14 (9\u201321)%  19 (9\u201330)%  1 year  31 (24\u201337)%  33 (25\u201341)%  32 (24\u201341)%  34 (22\u201347)%  Relapse          1 year  26 (20\u201332)%  27 (20\u201335)%  26 (18\u201334)%  25 (14\u201337)%  3 years  29 (23\u201335)%  29 (22\u201337)%  31 (23\u201340)% higher  33 (20\u201347)%  LFS           1 year  43 (36\u201350)%  40 (32\u201349)%  43 (34\u201351)%  42 (29\u201356)%  3 years  36 (29\u201343)%  27 (\u20132035)%  29 (21\u201339)%  23 (12\u201338)%  OS           100 days  77 (71\u201382)%  77 (70\u201383)%  81 (74\u201387)%  76 (64\u201387)%  1 year  50 (43\u201356)%  46 (38\u201354)%  53 (44\u201362)%  48 (35\u201361)%  3 years  39 (32\u201346)%  29 (22\u201337)%  30 (21\u201340)%  29 (17\u201343)% Follow-up (months)   36 (2\u201386)  40 (3\u201386)  35 (3\u201368)  36 (3\u201385) View Large"
}